risk stratification and secondary prevention following acute myocardial infarction in-ho chae...
TRANSCRIPT
![Page 1: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/1.jpg)
Risk stratification and Risk stratification and secondary prevention following secondary prevention following
acute myocardial infarctionacute myocardial infarction
In-Ho ChaeDepartment of Internal Medicine
Seoul National University Hospital
![Page 2: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/2.jpg)
Seoul National University Hospital
CAD – risk stratification in general
Symptom Past medical history Physical finding Rest 12-lead ECG Echocardiography Stress test
Exercise treadmill test Dipyridamole Tl/MIBI-Tc myocardial SPECT Dobutamine stress EchoCG
Myocardial enzyme
![Page 3: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/3.jpg)
Seoul National University Hospital
Risk at initial presentation of AMI
Clinical parameters Female Old age ( >70 yrs) DM Prior angina pectoris or previous MI
EKG Anterior wall MI Inferior wall MI with RV infarction ST change: multiple leads or high sum High grade block: > type 2 Morbitz, IVCD
![Page 4: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/4.jpg)
Seoul National University Hospital
Risk factors at initial presentation
![Page 5: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/5.jpg)
Seoul National University Hospital
Risk during hospital course
Recurrent ischemia Postinfarction angina
Reinfarction Silent ischemia
ECK change Holter monitoring
Non-Q-wave AMI Initial manif.: non-ST or ST elevation ACS Same as Q-wave AMI
![Page 6: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/6.jpg)
Seoul National University Hospital
Risk at hospital discharge
Prognostic factors for short- & long-term survival Resting LV function Residual ischemic myocardium Susceptibility to serious ventricular arrhythmia
Ventricular ectopic activity, electrical instability Patency of infarct-related artery Dx; EchoCG, stress test, EKG, CAG, etc
![Page 7: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/7.jpg)
Seoul National University Hospital
High risk following AMI
Consider aggressive management Recurrent ischemia at rest CHF or LV EF < 40% Sustained VT or VF >48 h post-MI
Not high risk Stress test: exercise ECG, RI scan
![Page 8: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/8.jpg)
Seoul National University Hospital
Echocardiography following AMI
Evaluating Infarct size Regional wall motion abnormality Global LV function Complication: MR, aneurysm, thrombi,
pericardial effusion Stress test
Dobutamine stress EchoCG: viability test
![Page 9: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/9.jpg)
Seoul National University Hospital
Stress test following AMI
Predischarge test for uncomplicated AMI Risk stratification of post-MI: prognosis Functional capacity Efficacy of current medication
Image: ECG, radionuclide scan, EchoCG Stress: exercise, vasodilator, dobutamine
![Page 10: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/10.jpg)
Seoul National University Hospital
Exercise ECG following AMI
Before discharge Submaximal exercise (5 mets): 4-6 days Symptom-limited exercise: 10-14 days
Early after discharge 14-21 days
Late after discharge 3-6 weeks after AMI Low risk or inadequate test at discharge
![Page 11: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/11.jpg)
Seoul National University Hospital
Myocardial SPECT following AMI
RI Scan > exercise ECG Pre-excitation Pacemaker rhythm LBBB or LVH >1mm ST change in resting ECG
RCA lesion
![Page 12: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/12.jpg)
Seoul National University Hospital
Assessment for electrical instability
High risk of sudden cardiac death after AMI QT dispersion: variability of QT interval Holter: ventricular arrhythmia EPS Signal-averaged ECG: delayed fragmented conductio
n Heart rate variability: beat-to-beat variability of RR in
terval Baroreflex sensitivity
![Page 13: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/13.jpg)
Seoul National University Hospital
![Page 14: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/14.jpg)
Seoul National University Hospital
Secondary prevention of AMI
Life style modification Lipid modification Antiplatelet agent ACE inhibitor Beta-adrenoreceptor blocker Antiarrhythmic Anticoagulant, nitrate, calcium antagonist Hormone replacement therapy
![Page 15: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/15.jpg)
Seoul National University Hospital
Life style and lipid modification
Stop smoking Blood pressure control Lipid risk
LDL > 100 mg/dl HDL < 40 mg/dl Statin: 30-40% reduction of cardiac mortality
CARE, 4S Niacin or gemfibrozil : TG & HDL !!
![Page 16: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/16.jpg)
Seoul National University Hospital
Cardiovascular drugs -1
Antiplatelet agents 25% reduction of recurrent infarction, stroke, vascul
ar death Aspirin, clopidogrel >> ticlopidine
ACE inhibitor Prevent ventricular remodeling Decrease recurrent ischemia, arrhythmia, CHF Ix; CHF, EF < 40%, RWMA
![Page 17: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/17.jpg)
Seoul National University Hospital
Cardiovascular drugs -2
Beta blocker 20% reduction of long-term mortality Early therapy < 6 hr of AMI
Calcium channel blocker Not routine Contraindication of beta blocker:
asthma etc- diltiazem, verapamil
Nitrate Not routine
![Page 18: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/18.jpg)
Seoul National University Hospital
Cardiovascular drugs -3
Anticoagulants Not routine; even combination with aspirin Ix: DVT, PTE, mural thrombi, large RWMA, Af, Hx of e
mbolic CVA Hormone replacement therapy
Not indicated in secondary prevention: HERS Can be continue in case of primary prevention
Antioxidant Not indicated
![Page 19: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/19.jpg)
Seoul National University Hospital
Cardiovascular drugs –4
Antiarrhythmic therapy Class I: no role Calss II: beta blocker – beneficial Class III
D,I-sotalol: possible benefit Dexsotalol: increase incidence of arrhythmia Amiodarone: reduce mortality
Class IV DHP - Nifedipine: maybe harmful ? Non-DHP diltiazem: beneficial
![Page 20: Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University](https://reader035.vdocument.in/reader035/viewer/2022072013/56649e4a5503460f94b3ef7e/html5/thumbnails/20.jpg)
Seoul National University Hospital
Drugs for secondary prevention of AMI
Aspirin Statin Beta blocker ACE inhibitor Proper antiarrhythmics as indicated
Life style modification